What should readers check next on AbbVie?

Check the earnings release footnotes for the adjustment items behind $0.11. Review the quarterly filing for the line items that separate $3.82 from $2.37. Watch the next results release to see whether a quarterly impact like $0.11 continues.

Which filings is this based on?

Form 8-K (Item 2.02,9.01) (SEC EDGAR, 2026-10-30).

Is this a buy recommendation?

No. This is for information only and is not investment advice. You are responsible for your own investment decisions and their results.

AbbVie Earnings: Adjusted EPS at $3.82

2 / 5

What changed

Adjusted diluted EPS

$3.82

Q3 2026

Diluted EPS (GAAP)

$2.37

Q3 2026

Unfavorable impact (per share)

$0.11

Q3 2026

Adjusted EPS in the quarter included an unfavorable $0.11 impact.
The unfavorable impact for 9M 2026 was $0.69.
Adjusted EPS was $3.82, while GAAP EPS was $2.37.

3 / 5

Context

The $0.69 cumulative impact was presented alongside the $0.11 quarterly impact.
The adjusted figure of $3.82 was disclosed alongside the GAAP figure of $2.37.

4 / 5

What to check next

UncertaintyCheck the earnings release footnotes for the adjustment items behind $0.11.
UncertaintyReview the quarterly filing for the line items that separate $3.82 from $2.37.
ConditionWatch the next results release to see whether a quarterly impact like $0.11 continues.

5 / 5

Sources and wrap-up

Next, watch the adjustment items behind the $0.11 impact.

Sources

Form 8-K (Item 2.02,9.01)SEC EDGAR, 2026-10-30

Facts used in the cards

Values and passages are copied from the original filings.

Diluted EPS (GAAP): $2.37: Q3 2026, SEC EDGAR; Diluted earnings per share (EPS) in the third quarter was $2.37 on a GAAP basis.
Adjusted diluted EPS: $3.82: Q3 2026, SEC EDGAR; Adjusted diluted EPS, excluding specified items, was $3.82. These results include an unfavorable impact of $0.11 per share related to acquired IPR D and milestones expense.
Unfavorable impact (per share): $0.11: Q3 2026, SEC EDGAR; These results include an unfavorable impact of $0.11 per share related to acquired IPR D and milestones expense.
YTD unfavorable impact: $0.69: 9M 2026, SEC EDGAR; AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR D and milestones expense incurred year-to-date through the third quarter 2026.

Questions and answers

What was AbbVie's adjusted diluted EPS in Q3 2026?: $3.82.
What was AbbVie's diluted EPS (GAAP) in Q3 2026?: $2.37.
What was AbbVie's unfavorable impact (per share) in Q3 2026?: $0.11.
What should readers check next on AbbVie?: Check the earnings release footnotes for the adjustment items behind $0.11. Review the quarterly filing for the line items that separate $3.82 from $2.37. Watch the next results release to see whether a quarterly impact like $0.11 continues.
Which filings is this based on?: Form 8-K (Item 2.02,9.01) (SEC EDGAR, 2026-10-30).
Is this a buy recommendation?: No. This is for information only and is not investment advice. You are responsible for your own investment decisions and their results.

Key terms

Separate basis: Figures for the company alone, leaving out its subsidiaries.
EPS: Net income divided by the number of shares: the profit earned per share.
GAAP: US accounting standards. Figures prepared under them are the official results.
Adjusted figures: Numbers a company recalculates after removing items such as one-off costs. Accounting standards do not define them, and methods differ by company.
Diluted EPS: Earnings per share counting securities that could still turn into shares.

Corrections

No corrections.

Also in this edition

Oct. 30, 2026USAmazonEarnings

AWS growth came in at 39%

The results confirmed 12% net sales growth, 13.9% operating margin, and 39% AWS growth.